FDA approves Jubilant Life Sciences’ quetiapine fumarate tablets
NOIDA, India — The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.
Jubilant announced the approval of quetiapine fumarate tablets in the 25-mg strength. The drug is a generic version of AstraZeneca’s Seroquel.
Various versions of the drug have annual sales of about $59 million, according to IMS Health.
Sandoz to market authorized generic version of Adderall XR
PHILADELPHIA — Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.
Shire said Sandoz, the generics division of Swiss drug maker Novartis, would market an authorized generic version of Adderall XR (amphetamine; dextroamphetamine).
Under the five-year agreement, which became effective Sunday, Sandoz will begin marketing the product starting in July 2016. Shire will manufacture the drug, while Sandoz will market it and provide royalties on sales to Shire.
Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under a contract between the branded drug’s manufacturer and a third-party company.
Study finds better adherence among patients in medication-synchronization programs
WASHINGTON — Patients who received appointment-based medication synchronization were up to six times more likely to adhere to their therapies than those who didn’t, according to a study of patients at rural Thrifty White Pharmacy locations in the Midwest published in the Journal of the American Pharmacists Association.
The study, which appears in JAPhA‘s November/December issue, found that patients in the appointment-based medication synchronization, or ABMS group, were 3.4-6.1 times more likely to be adherent, while those in the control group were 52% to 73% more likely to stop taking chronic medications over the course of a year. Overall, the patients in the ABMS program showed adherence rates of 66.1% to 75.5% over the year, compared with 37% to 40.8% among control patients. The study took place in rural pharmacies in the Midwest between June 30, 2011 and Oct. 31. 2012.
"This research shows appointment-based medication synchronization to be one of the most effective interventions available to help patients take their medications," lead study author and Virginia Commonwealth University pharmacy professor David Holdford said. "Widespread implementation in pharmacies across the United States can have a major impact on patient health."